Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
National Institutes of Health Clinical Center (CC)
ViroMissile, Inc.
Eisai Inc.
Children's Oncology Group
SEED Therapeutics, Inc.
Seattle Children's Hospital
St. Jude Children's Research Hospital
MacroGenics
City of Hope Medical Center
Ocellaris Pharma, Inc.
M.D. Anderson Cancer Center
Mayo Clinic
Sotio Biotech Inc.
National Institutes of Health Clinical Center (CC)
GlaxoSmithKline
St. Jude Children's Research Hospital
Milton S. Hershey Medical Center
Baylor College of Medicine
HiFiBiO Therapeutics
Gazi University
GONGCHU Biotechnology Co., Ltd
Jonsson Comprehensive Cancer Center
Telix Pharmaceuticals (Innovations) Pty Limited
Children's National Research Institute
GI Innovation, Inc.
TopAlliance Biosciences
National Cancer Institute (NCI)
Xencor, Inc.
National Cancer Institute (NCI)
BioEclipse Therapeutics
Cellestia Biotech AG
Peking Union Medical College Hospital
Children's National Research Institute
Tempest Therapeutics
Institut Bergonié
Stanford University
Roswell Park Cancer Institute
Hospital Universitario Virgen de la Arrixaca
Eli Lilly and Company
Shenzhen BinDeBio Ltd.
Pfizer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
Impaqtt Foundation
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals